MedTrace Logo

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT07107204 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2025-09-17

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between 18(inclusive) and 70 years .

Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.

Conditions

  • Relapsed or Refractory Hematologic Malignancies
  • Leukemia
  • Lymphoma
  • Multiple Myeloma (MM)

Interventions

DRUG

BT02

BT02 monoclonal antibody injection with intravenous administration every 2 or 3 weeks

Sponsors & Collaborators

  • Biotroy Therapeutics

    lead INDUSTRY

Principal Investigators

  • Ying Wang, MD · Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-31
Primary Completion
2028-01-31
Completion
2028-04-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07107204 on ClinicalTrials.gov